Peptides and Compounded Medications

What You Need to Know

Creator: James Whynot, MD
Published: 2026-07-28T12:37:13-04:00

Reviewed by James Whynot, MD

Introduction from Dr. Whynot

Peptides have been in the news lately, and many patients have been asking questions about them. Here is the latest report about the FDA discussing compounding formulas and what they think about four peptides. This is an interesting read from Healio:
Original Article By Emma Bascom
Fact checked by Mindy Valcarcel, MS

As interest in peptide therapies continues to grow, the FDA's Pharmacy Compounding Advisory Committee recently met to evaluate whether several peptides should be permitted for compounding by licensed pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Important: These recommendations do not mean that the peptides have been FDA-approved. The recommendations concern whether licensed compounding pharmacies may be permitted to prepare them for individual patients when prescribed by a qualified healthcare professional.

Why This Meeting Matters

On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides that have attracted significant public interest for conditions ranging from inflammatory disease and wound healing to insomnia, obesity, osteoporosis, and neurological disorders.

The committee evaluated whether these substances should be added to the FDA's 503A Bulk Drug Substances List. Inclusion on this list may allow state-licensed physicians and pharmacists to compound medications containing the listed substances for individual patients.

FDA officials emphasized that compounded medications are not FDA-approved. They have not undergone the same review for safety, effectiveness, manufacturing quality, and consistency that is required for commercially approved medications.

Four Peptides That Received Significant Attention

BPC-157

BPC-157 received one of the longest discussions during the meeting. It was evaluated primarily in relation to ulcerative colitis, although it is frequently promoted elsewhere for tissue healing, injury recovery, and other uses.

The committee voted 8-6-1 in favor of recommending both the free-base and acetate forms for addition to the 503A list.

Supporters argued that allowing licensed pharmacies to compound BPC-157 could reduce patient reliance on unregulated overseas suppliers and products sold as research chemicals.

Opponents expressed concern about the lack of randomized controlled clinical trials, limited human effectiveness data, and unresolved safety questions.

KPV

KPV was evaluated for inflammatory conditions and wound healing.

The committee voted 8-6-1 to recommend adding both the free-base and acetate forms of KPV to the compounding list.

Those supporting the recommendation believed that allowing physician-directed compounding could create additional opportunities to collect clinical experience and better characterize the peptide.

Those voting against the recommendation cited poorly defined clinical indications, uncertain absorption, possible allergic or immune reactions, and insufficient evidence demonstrating effectiveness.

TB-500

TB-500 is frequently discussed for tissue repair, wound healing, and exercise-related recovery.

The committee voted 8-6-1 to recommend adding both the acetate and free-base forms to the 503A list.

Supporters emphasized that patients are already obtaining these products from questionable online sources. They argued that prescription-based preparation by a licensed compounding pharmacy could provide better quality controls than anonymous research-grade products.

Opponents highlighted the lack of meaningful human clinical studies. Concerns were also raised regarding possible tumor progression, metastasis, uncertain dosing, and the use of TB-500 in combination with other peptides.

MOTS-c

MOTS-c has generated interest because of its possible relationship to metabolism, obesity, bone health, and osteoporosis.

The committee voted 7-5-2 to recommend adding both forms of MOTS-c to the list.

Some committee members cited concerns regarding limited clinical evidence, injectable medication risks, uncertain dosing, and possible immune reactions.

Others believed that allowing licensed compounding could provide a more controlled environment for physician-supervised use and further study.

Other Peptides Reviewed

Peptide	Committee Vote	Recommendation
Epitalon	7-4-1	Recommended
Semax	8-5-1	Recommended
Emideltide	6-7-1	Not recommended

An Important Distinction

One of the most important messages from the meeting was that these committee votes do not approve any peptide for medical use.

A positive recommendation means only that the advisory committee believes a substance should be considered for inclusion on the 503A Bulk Drug Substances List.

The FDA is not required to accept the committee's recommendations. Additional agency review and formal rulemaking are still required before the recommendations can become final.

Therefore, a favorable committee vote should not be interpreted as proof that a peptide has been shown to be safe or effective for a particular condition.

The Ongoing Debate

The discussions highlighted a significant divide among committee members.

Those supporting broader access argued that patients are already purchasing peptides from unregulated internet vendors. In their view, prescribing through a licensed clinician and obtaining a product from a regulated compounding pharmacy may be safer than purchasing an unidentified vial from an overseas supplier.

Those opposing the recommendations emphasized that many of these peptides still lack high-quality randomized clinical trials demonstrating safety, effectiveness, appropriate dosing, and long-term outcomes.

Both sides appeared to agree on one central issue: substantially more research is needed.

What This Means for Patients

These peptides are not FDA-approved medications.
The advisory committee's votes are recommendations and are not final FDA decisions.
A recommendation for compounding does not establish that a peptide is safe or effective.
Licensed compounding pharmacies operate under more oversight than anonymous online research-chemical vendors.
Compounded medications may still carry significant risks, including contamination, incorrect potency, sterility problems, immune reactions, side effects, and unknown long-term consequences.
Peptides should not be purchased from websites labeling products “for research use only” or “not for human consumption.”
Any decision regarding a compounded peptide should involve a qualified healthcare professional who understands the patient's complete medical history and current medications.

My Perspective

As physicians, we must balance patient access, patient autonomy, safety, and evidence-based medicine. The recent FDA committee discussions illustrate how challenging that balance can be.

There is legitimate scientific interest surrounding peptides. However, scientific interest should not be confused with proof that a treatment works.

Patients deserve an honest discussion about what is known, what remains uncertain, and whether a proposed treatment is supported by meaningful clinical evidence.

A product being available from a compounding pharmacy does not automatically mean that it is appropriate for every patient. Decisions should be individualized and should include a careful review of possible benefits, risks, alternatives, medication interactions, and the quality of the available evidence.

As additional research emerges and the FDA continues its review process, our understanding of these compounds will continue to evolve.

Medical Disclaimer

This article is provided for general educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment and does not establish a physician-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, peptide, supplement, or treatment program.